Fisher & Paykel Healthcare Corporation Limited advises that the strike price for the dividend reinvestment plan (DRP) operating in respect of the dividend payable on Friday 8 July 2016 has been set at NZ$10.3266 per share. The strike price is calculated as the volume weighted average sale price for an ordinary share calculated on all price setting trades of shares which took place through the NZSX over a period of 5 trading days immediately following the dividend record date of 17 June 2016.
Shareholders who have elected to participate in the DRP reinvest their dividends to receive additional shares, rather than cash. The number of Fisher & Paykel Healthcare shares to which participants are entitled is calculated by multiplying the net dividend per share by the number of that participant’s participating shares and then dividing that number by the issue price of NZ$10.3266.
The company also advises that the foreign exchange rate used for the payment of the dividend on 8 July 2016 to Australian investors in AUD has been set at 0.9549.
Contact: Tony Barclay, Company Secretary on +64 9 574 0119. For more information about the company visit www.fphcare.com
DRP strike price and AUD FX rate for final dividend
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment